Shares in Merus NV ($MRUS) surged by 30% following the publication of an abstract at the ASCO 2024 conference, highlighting promising phase 2 trial results of their bispecific antibody petosemtamab in combination with pembrolizumab for treating head and neck cancer. The combination therapy showed an objective response rate (ORR) of 60% in refractory head and neck cancer patients, significantly higher than the 37% ORR observed with petosemtamab as a monotherapy. The drug candidate has already received Breakthrough Therapy Designation. Meanwhile, Verastem Inc. experienced a sharp decline in its stock price, dropping by 60% after reporting serious adverse events and a reduced ORR from 45% to 27% in their rolling NDA submission for the combination treatment of Avutometinib and Defactinib in KRAS mutant low-grade serous ovarian cancer.
📣 Join us for a dynamic #ASCO24 symposium: 📝 Unraveling cMET and MET: Transforming NSCLC Management 📍 Room: Continental A, Hilton Chicago 📆 June 2 ⏰ 6:45 PM CT 🔗 https://t.co/oEH5w76knD @DRCamidge @IbiayiMD https://t.co/1s2mUZ5PmJ
As research in AML continues to pick up ground, examining approaches targeting menin and TP53 mutations are top of mind for investigators to push for further progress. @UMNCancer #AML #MDS #oncology https://t.co/lOeNYGmFaq https://t.co/ZTYZjPBDxA
Dr @VincentRK of @MayoClinic discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting. @ASCO #ASCO24 #mmsm https://t.co/d2lE8nmZ49
https://t.co/zNsg4yBRuP. @mtmdphd @SuyogCancer @kevinpunie top #asco24 trials with top buzz. Any surprises so far? https://t.co/AvLIEFITtG
Dr @StephenVLiu of @LombardiCancer discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC. @ASCO #ASCO24 #lcsm https://t.co/Ujlfiq6eZk
Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments. @ckitko @VUMC_Cancer #leusm #oncology https://t.co/quoPnrVM1Z
Dr Sumanta Kumar Pal, MD, FASCO, of @cityofhope discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting. @montypal @ASCO #ASCO24 #kcsm https://t.co/qvLX4RelWR
Epoch 21: SPECIAL EDITION - ASCO 2024 🏭#1 Pharma Merck, AbbVie, J&J, Pfizer, AZ,BMS, Lilly, Bayer, Daiichi, Takeda, Eisai 🧬#2 Biotech 📭Conditional Activation Xilio (IL-2), Werewolf (IL-2), Aulos (IL-2), BioAtla (CTLA4 CAB) 💊Small Mol I-O Nimbus (HPK1) 🦠Cell Therapy… https://t.co/OUaKjkipnf
Patients with lymphoma have gained treatment options with the wave of CAR T-cell therapy FDA approvals in recent years, but more work is required to find better methods to overcome mechanisms of resistance to these agents. @MDAndersonNews #lymsm #oncology https://t.co/F0pAoyFuB8 https://t.co/JKGHZ3byDv
Investigators aim to best understand how tumor and immune microenvironmental cells interact in the context of immune checkpoint blockade, and how to apply these insights in the clinic. @VanAllenLab @danafarber @harvardmed @nyasciences #kcsm #oncology https://t.co/EpFEZ7BJCD https://t.co/f8Veh4AZKf
BioCentury's latest Clinical Report: Merus data stand out among #ASCO24 highlights https://t.co/TW2woJzaYd
Less than a week to what promises to be a terrific ASCO24. Multiple trials with practice changing potential, including with ADCs challenging our HER2 categories, CDK4/6 inhibitors beyond progression, adjuvant IO for TNBC and much more. See you in Chicago next week! #bcsm #ASCO24 https://t.co/AWJby4PnPQ
Where can we expect innovation, and what are the biggest challenges ahead in cancer research? Hear from top officials at some of the largest companies working in cancer today at #STATatASCO. Register: https://t.co/oiEEOrpHKb https://t.co/vOXYWA0nkB
Thank you Dr @neerajaiims for highlighting our work! Excited to present our findings regarding this IL7 SNP’s association with irAEs in pts with mRCC @ASCO #ASCO24 Huge thanks to my incredible mentors @DrChoueiri @SashaGusevPosts @VanAllenLab for their guidance and support https://t.co/X1bMdFfd6R
The work of @eddy_saad @VanAllenLab @SashaGusevPosts being highlighted here #ASCO24 ==> we again validate SNP in IL-7 to be associated with irAEs! @DanaFarber_GU @DanaFarber @ASCO #Dana9team @OncoAlert https://t.co/u9Dr8Xhvze
Ab#4506 @ASCO #ASCO24 by @AlbigesL @brian_rini 👉https://t.co/z7UddTZiWR👉 Ph2 IMmotion010 trial of adj atezolizumab vs. placebo #kidneycancer👉⬆️baseline serum KIM-1 levels ➡️poorer prognosis & ⬆ outcomes with atezolizumab vs. placebo 👇 @OncoAlert @urotoday @Uromigos https://t.co/6BXrhNSZIg
Ab#12140 @ASCO #ASCO24 by @eddy_saad👉 https://t.co/Fb74GaKDUK👉Analysis of CheckMate 025 ph3 NIVO vs. everolimus in pts w/ mRCC #kidneycancer👉germline IL7 SNP associated w/ ⬆️ rates of AEs in pts treated w/ NIVO but not w/ EVE @DrChoueiri @OncoAlert @urotoday @kidneycan https://t.co/ZsXE09gsTY
Adam Feuerstein's high-level read on #ASCO24 is that this will be an incremental meeting in terms of stock-moving data. More on what to expect in a new edition of his newsletter here: https://t.co/0Vo7iHzkzA
A recent study led by @RossFirestone, @szusmani, and @DavidJChungMD evaluated mechanisms of resistance to teclistamab, a CD3 x BCMA bispecific antibody, in people with #multiplemyeloma. #mmsm @MSKCancerCenter @BloodJournal Read the study: https://t.co/KlmnpxO9f5 https://t.co/gtYsHAXgvN
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know. https://t.co/yT5fztdMEy
Recent buy $MRUS up 30 pct on ASCO abstract. ORR increased to 60 pct in combination with Keytruda in refractory head and neck cancer compared to 37 pct as mono therapy. Very strong data. The drug candidate already has Breakthrough therapy designation in this cancer. #stocks…
Attending the @ASCO Annual Meeting next week? Visit the American Cancer Society Booth # 11031 and meet the experts! #ASCO2024 https://t.co/FoX2gdISwf
$MRUS is a key biotech winner of the #ASCO24 abstract drop https://t.co/YzLh5eSu4v $IOVA $IMCR $GMAB $TNGX $VSTM $CADL
$VSTM shady management
New biomarker predicts success of #immunotherapy in #kidneyCancer @NatureMedicine https://t.co/jVt4iteX6r
$VSTM snatches defeat from the jaws of an #ASCO24 victory. Via @ApexOnco -> https://t.co/T41990UyRq
Not bad for another big-pharma #ASCO24 $MRUS +25% $IOVA +1% $IMCR -14% $CADL -20% $VSTM -60%
📣 FINALLY sharing our #ASCO24 abstract: Identifying challenges w/ research in a regional CareNetwork. Surveyed 218 network MDs,found 3 🔑 issues & as a result contributed towards : ⭐️⬆️ accruals ⭐️⬆️ support staff ⭐️⬆️ protocols OTA @DianeReidyLagun @RielyMD @MSKCancerCenter https://t.co/CL89MsRXX8
$VSTM (-59.1% pre) Verastem whipsaws after updates for cancer drug combo - SA https://t.co/9zZ8scpuBg
$MRUS (+21.4% pre) Merus (MRUS) Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting - SI https://t.co/yHmTweuOt0
$VSTM -60% “As of the May 14, 2024 data cutoff, 12 patients experienced 19 treatment emergent serious adverse events (SAEs), 11 patients with grade ≥3
$VSTM what happened?
$VSTM with a couple of bombshells. AA filing reduced to KRAS mt LGSOC and ORR seemingly gone down from 45% to 27%. ORR seems to be missing from PR https://t.co/jS5wo0xzCD
Whoa $VSTM. Initially +45% after hours, now -60%. WTF https://t.co/pNkmJA97gs
Artera is excited to participate in #ASCO24! Don't miss the oral presentation from Daniel Kates-Harbeck of @LMU_Uniklinikum and presentations from @markowskiguonc and Philip Sutera of @JohnsHopkins during the poster session! #ArteraOnTheGo #CancerTreatment #ProstateCancer https://t.co/NNS0Owz2E0
Everyone liked $VSTM Ah, now down 55% pre!
👀 $MRUS 50-60% ORR in Head&Neck https://t.co/5MDjAaS5Cg
REMINDER: $BHVN R&D Day: 5/29 *the coming week is going to be HEAVY oncology talk with ASCO - this will be a nice break for those in units operating outside the war on cancer ⭕️ https://t.co/Pnj10tOs07 https://t.co/JJSIBlQiUG https://t.co/6VycBlycwO
$VSTM CC at 8 am ET to provide update on RAMP 201 and rolling NDA submission https://t.co/ggIvhJ6ENz
$VSTM CC 4 at 8 am ET to provide update on RAMP 201 and rolling NDA submission https://t.co/ggIvhJ6ENz
Will try to run through the #ASCO abstracts to give you our take on the under-radar / emerging projects we note. Sunday we will share additional commentary on R&D productivity beyond the standard clinical metric (survival, cycle times) which we shared last Sunday. Monday we… https://t.co/qoDppvMX7y
$VSTM Initiates Rolling Submission of NDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Some claudin 18.2 data from #ASCO24. An ADC that i think $BMY has shelved LM-302 with a 30.6% ORR in gastric/GEJ (https://t.co/4BJX1xKCu9) , Innovent IBI343 40% ORR in PDAC (https://t.co/2HLT0oFeGa), Carsgen CAR-T 57.4% ORR in gastric (https://t.co/b98GjgXNJE)
Shares in @MerusNV spike on #ASCO24 abstract on phase 2 trial of EGFRxLGR5 bispecific petosemtamab in head and neck cancer. $MRUS #oncology https://t.co/H9e9Q3NJHF